India's one-shot dengue vaccine 'DengiAll' reaches 70% enrolment in Phase III trials across 20 national sites.

Seventy per cent enrolment of participants for the Phase III clinical trial of the indigenous one-shot dengue vaccine, DengiAll, has been completed, Minister of State for Health, Prataprao Jadhav, ...

Key Points GAAP revenue surpassed expectations, reaching $12.5 million in Q2 2025, Revenue reached $12.5 million, up approximately 45.3% from the prior year period. Net loss (GAAP) widened to $112.0 ...

Zoryve’s regulatory and commercial success, together with pipeline progress, supports Arcutis Biotherapeutics’ positive Q2 ...

Weight loss medications like Wegovy can be life-changing for people living with obesity or excess weight with related health ...

AI offers promise in the realm of chronic disease management, including diabetes, obesity, and PCOS, but must be approached with caution.

FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development ...

Q2 2025 Earnings Call Transcript July 30, 2025 Pulmonx Corporation beats earnings expectations. Reported EPS is $-0.38, ...

Sodium can raise your blood pressure by increasing blood volume and narrowing blood vessels. Learn who's most at risk and ...

Oculis Holding AG (Nasdaq: OCS; XICE: OCS) ('Oculis” or the 'Company”), a global biopharmaceutical company focused on ...